Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term androgen deprivation. Found 17 abstracts

Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CA, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. Cancer. 2017 Jul;123(13):2489-96.   PMCID: PMC5474197
Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CA, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. Cancer. 2017 Mar 21;.
Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA. Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 Sep;10(9):1081-7.   PMCID: Not NIH Funded
Turaka A, Buyyounouski MK, Hanlon AL, Horwitz EM, Greenberg RE, Movsas B. Hypoxic Prostate/Muscle PO2 Ratio Predicts for Outcome in Patients With Localized Prostate Cancer: Long-Term Results. International Journal of Radiation Oncology Biology Physics. 2012 Mar;82(3):E433-E439.   PMCID: not NIH funded
Hamstra DA, Bae K, Pilepich MV, Hanks GE, Grignon DJ, McGowan DG, Roach M, Lawton C, Lee RJ, Sandler H. OLDER AGE PREDICTS DECREASED METASTASIS AND PROSTATE CANCER-SPECIFIC DEATH FOR MEN TREATED WITH RADIATION THERAPY: META-ANALYSIS OF RADIATION THERAPY ONCOLOGY GROUP TRIALS. International Journal of Radiation Oncology Biology Physics. 2011 Dec;81(5):1293-301.   PMCID: NIHMS285956
Klayton TL, Ruth K, Horwitz EM, Uzzo RG, Kutikov A, Chen DY, Sobczak M, Buyyounouski MK. Young age under 60 years is not a contraindication to treatment with definitive dose escalated radiotherapy for prostate cancer. Radiotherapy and Oncology. 2011 Dec;101(3):508-12.   PMCID: PMC3225561
Chen LL, Mu ZM, Hachem P, Ma CM, Wallentine A, Pollack A. MR-guided focused ultrasound: enhancement of intratumoral uptake of H-3 -docetaxel in vivo. Physics in Medicine and Biology. 2010 Dec;55(24):7399-410.   PMCID: not NIH funded
Pollack A, Bae K, Khor LY, Al-Saleem T, Hammond ME, Venkatesan V, Byhardt RW, Asbell SO, Shipley WU, Sandler HM. The Importance of Protein Kinase A in Prostate Cancer: Relationship to Patient Outcome in Radiation Therapy Oncology Group Trial 92-02. Clinical Cancer Research. 2009 Sep;15(17):5478-84.   PMCID: PMC2763098
Ray ME, Bae K, Hussain MH, Hanks GE, Shipley WU, Sandler HM. Potential Surrogate Endpoints for Prostate Cancer Survival: Analysis of a Phase III Randomized Trial. Journal of the National Cancer Institute. 2009 Feb;101(4):228-36.   PMCID: PMC2734115
Khor LY, DeSilvio M, Li RL, McDonnell TJ, Hammond ME, Sause WT, Pilepich MV, Okunieff P, Sandler HM, Pollack A. Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2006 Sep;66(1):25-30.
Hayes SB, Pollack A. Parameters for treatment decisions for salvage radiation therapy. Journal of Clinical Oncology. 2005 Nov 10;23(32):8204-11.
Khor LY, DeSilvio M, Al-Saleem T, Hammond ME, Grignon DJ, Sause W, Pilepich M, Okunieff P, Sandler H, Pollack A. MDM2 as a predictor of prostate carcinoma outcome - An analysis of Radiation Therapy Oncology Group Protocol 8610. Cancer. 2005 Sep;104(5):962-7.
Konski A, Sherman E, Krahn M, Bremner K, Beck JR, Watkins-Bruner D, Pilepich M. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10). International Journal of Radiation Oncology Biology Physics. 2005 Nov;63(3):788-94.
Nguyen KH, Hachem P, Khor LY, Salem N, Hunt KK, Calkins PR, Pollack A. Adenoviral-E2F-1 radiosensitizes p53(wild-type) and P53(null) human prostate cancer cells. International Journal of Radiation Oncology Biology Physics. 2005 Sep;63(1):238-46.
Li RL, Heydon K, Hammond ME, Grignon DJ, Roach M, Wolkov HB, Sandler HM, Shipley WU, Pollack A. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: An analysis of patients in radiation therapy oncology group protocol 86-10. Clinical Cancer Research. 2004 Jan;10(12):4118-24.
Anderson PR, Hanlon AL, Movsas B, Hanks GE. Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation. International Journal of Radiation Oncology Biology Physics. 1997 Dec;39(5):1025-30.
Schultheiss TE, Lee WR, Hunt MA, Hanlon AL, Peter RS, Hanks GE. Late GI and GU complications in the treatment of prostate cancer. International Journal of Radiation Oncology Biology Physics. 1997 Jan;37(1):3-11.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term androgen deprivation

androgen deprivation radiotherapy radiation-therapy carcinoma radiation radical prostatectomy prostate cancer expression therapy biochemical failure trial apoptosis docetaxel survival external-beam radiation definitive radiotherapy postprostatectomy Prostate cancer high risk chemotherapy group protocol 92-02 radiation therapy antigen risk adjuvant phase-iii trial p53 in-vivo cells prostate-specific antigen disease-free survival Brachytherapy Age factors Nuclear Medicine & Medical Imaging Radiology receptor Prostate genes cost-effectiveness psa doubling time Male E2F-1 therapy oncology group Hypoxia agonists Antineoplastic Agents prostate-specific dna-damage dose-escalation brain ki-67 labeling index advanced-carcinoma lung-cancer group rtog Kallikreins postoperative radiotherapy Oncology Nitriles adenocarcinoma neoadjuvant hormonal-therapy competing risk Adult model pathway androgen deprivation MDM2-radiotherapy-distant metastasis Conformal assessing biochemical failure Middle Aged blood surgery Multivariate Analysis toxicity prostate-cancer cells estrogen s-phase entry morbidity Tosyl Compounds Adjuvant Chemoradiotherapy positron-emission-tomography pathology Eppendorf colon-cancer rtog-8610 prognostic-significance hormonal-therapy immunohistochemical analysis Proportional Hazards Models Taxoids Prostatectomy Anilides Hormonal ablation Prostatic Neoplasms dose-rate brachytherapy cell-proliferation angiogenesis Intensity-Modulated Radiotherapy liver-tumors bromodeoxyuridine Biochemical failure damage locally advanced-carcinoma methods men younger Adenocarcinoma Radiation therapy Radiotherapy deprivation adjuvant therapy recurrence competing neoadjuvant population Age external-beam radiotherapy Androgen Antagonists nerve-sparing prostatectomy decision-analysis markers Gonadotropin-Releasing Hormone follow-up dna-ploidy adenoviral gene therapy randomized prostate abiraterone acetate oxygenation tumor p53 gene-therapy mortality postprostatectomy radiotherapy economic analysis Conformal Radiotherapy dose response androgen ablation Disease-Free Survival cancer cells Prostate-Specific Antigen bax tumor-growth Aged Metastasis patient age flutamide Neoplasm Staging drug-delivery p53-independent apoptosis therapeutic use transcription factor e2f-1 Neoplasm Grading Prostatic neoplasms
Last updated on Monday, July 06, 2020